Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

Title

Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)

Authors

Keywords

-

Journal

AMERICAN HEART JOURNAL

Volume 222, Issue -, Pages 183-190

Publisher

Elsevier BV

Online

2020-01-21

DOI

10.1016/j.ahj.2020.01.009